PERIPHERAL T-CELL LYMPHOMA
Clinical trials for PERIPHERAL T-CELL LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new PERIPHERAL T-CELL LYMPHOMA trials appear
Sign up with your email to follow new studies for PERIPHERAL T-CELL LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Experimental lymphoma combo trial halted early
Disease control TerminatedThis study tested a drug called selinexor combined with chemotherapy or another drug (tislelizumab) in 56 adults with relapsed or hard-to-treat T-cell or NK-cell lymphoma. The goal was to see if the combination was safe and could shrink tumors. The trial was stopped early, so res…
Matched conditions: PERIPHERAL T-CELL LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: Antengene Corporation • Aim: Disease control
Last updated May 26, 2026 04:32 UTC
-
Experimental combo for rare blood cancer tested, but study halted early
Disease control TerminatedThis early-phase trial tested a combination of two drugs, parsaclisib and chidamide, in 12 people with a rare blood cancer called peripheral T-cell lymphoma that had come back or stopped responding to treatment. The main goal was to find a safe dose and check for side effects. Th…
Matched conditions: PERIPHERAL T-CELL LYMPHOMA
Phase: PHASE1 • Sponsor: Henan Cancer Hospital • Aim: Disease control
Last updated May 26, 2026 04:29 UTC
-
New drug combo tested for advanced cancers: hope for lymphoma and solid tumors
Disease control TerminatedThis early-phase study tested a new experimental drug, PF-08046032, alone or combined with another drug (sasanlimab) in 6 adults with advanced lymphomas or solid tumors that had spread or stopped responding to standard treatments. The main goals were to check safety and find the …
Matched conditions: PERIPHERAL T-CELL LYMPHOMA
Phase: PHASE1 • Sponsor: Pfizer • Aim: Disease control
Last updated May 26, 2026 04:24 UTC